Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.37 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863596 | 0.82 | ESR1 (0.46) | HRH3LTA4HPTGS2KDM4EPOLB | |
| SCHEMBL5863480 | 0.82 | LTA4H (0.40) | HRH3LTA4HKCNH2KDM4E | |
| SCHEMBL5863902 | 0.79 | KDM4E (0.40) | HRH3KCNH2KDM4EPOLB | |
| SCHEMBL5863824 | 0.76 | LTA4H (0.47) | HRH3LTA4HPTGS2KCNH2 | |
| SCHEMBL5863827 | 0.75 | LTA4H (0.37) | HRH3LTA4HKCNH2KDM4E | |
| SCHEMBL5863302 | 0.75 | LTA4H (0.47) | HRH3LTA4HPTGS2KCNH2KDM4E | |
| SCHEMBL5863643 | 0.75 | ESR1 (0.49) | LTA4H | |
| SCHEMBL5863662 | 0.75 | LTA4H (0.45) | HRH3LTA4HKCNH2 | |
| SCHEMBL5864087 | 0.74 | ESR1 (0.45) | HRH3LTA4HKCNH2KDM4E | |
| SCHEMBL5864049 | 0.74 | TP53 (0.40) | LTA4HKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7053212-B2 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | PFIZER INC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110767-A1 | Acyclic amide and sulfonamide ligands for the estrogen receptor | GHSR, GPER1, SSTR1 | HRH3 1036/4885LTA4H 1687/4885PTGS2 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.